%20--%3e%3csvg%20width='63.297821mm'%20height='39.29665mm'%20viewBox='0%200%2063.297821%2039.29665'%20version='1.1'%20id='svg8765'%20inkscape:version='1.1%20(c4e8f9ed74,%202021-05-24)'%20sodipodi:docname='OBALogoSingle2.svg'%20xmlns:inkscape='http://www.inkscape.org/namespaces/inkscape'%20xmlns:sodipodi='http://sodipodi.sourceforge.net/DTD/sodipodi-0.dtd'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:svg='http://www.w3.org/2000/svg'%3e%3csodipodi:namedview%20id='namedview8767'%20pagecolor='%23ffffff'%20bordercolor='%23666666'%20borderopacity='1.0'%20inkscape:pageshadow='2'%20inkscape:pageopacity='0.0'%20inkscape:pagecheckerboard='0'%20inkscape:document-units='mm'%20showgrid='false'%20fit-margin-top='0'%20fit-margin-left='0'%20fit-margin-right='0'%20fit-margin-bottom='0'%20inkscape:zoom='1.1759259'%20inkscape:cx='179.85827'%20inkscape:cy='102.04724'%20inkscape:window-width='1920'%20inkscape:window-height='972'%20inkscape:window-x='0'%20inkscape:window-y='27'%20inkscape:window-maximized='1'%20inkscape:current-layer='layer1'%20/%3e%3cdefs%20id='defs8762'%20/%3e%3cg%20inkscape:label='Layer%201'%20inkscape:groupmode='layer'%20id='layer1'%20transform='translate(-31.351095,-50.101677)'%3e%3cpath%20style='fill:none;stroke:%233584e4;stroke-width:3.965;stroke-linecap:square;stroke-linejoin:round;stroke-miterlimit:4;stroke-dasharray:none;stroke-opacity:1'%20d='m%2077.07508,77.78787%2014.84134,8.87817%20V%2052.83397%20L%2034.08359,86.5521%20V%2053.69366%20l%2015.27351,9.31107'%20id='path8388'%20sodipodi:nodetypes='cccccc'%20/%3e%3c/g%3e%3c/svg%3e)
Genomma Lab Internacional S.A.B. de C.V(GNMLF) Stock Analysis | Healthcare
Market Performance
Stock returned +10.0% over the past year, broadly in line with market conditions.What is Genomma Lab Internacional S.A.B. de C.V?
, together with its subsidiaries, provides pharmaceutical and personal care products primarily in Mexico and internationally.
GNMLF · Verdict
Moderate reward · low risk
GNMLF stands out on volatility and valuation, but watch the growth signal.
Based on 88% data coverage
GNMLF · Verdict
What’s working & what to watch
Strengths 4
- Volatility95/100
Top decile vs peers
- Valuation84/100
P/E 9.3× · PEG 0.86
- Profitability68/100
9% net margin · 14% ROE
- Cash flow67/100
5% free-cash-flow margin
Watchouts 1
- Growth38/100
Rev +4.1% CAGR · earnings +7.8%
Model-based scoring. For information only — not financial advice.
What is Genomma Lab Internacional S.A.B. de C.V?
, together with its subsidiaries, provides pharmaceutical and personal care products primarily in Mexico and internationally. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products to prevent hair loss, ointment for muscle pain, anti-fungal treatments for the relief of colitis, products to counter stress levels, anti-wrinkles, antacids, anti-ulcers, anti-flu, protection and improvement products, treatments against hemorrhoids, against varicose veins, osteoarthritis, ophthalmic medications, infant nutrition, and others. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 1.05B, and a P/E ratio of 12.0x.
Financial Highlights
Investment Breakdown
Analysis
Reward: Moderate (54)The scoring profile indicates limited reward potential at this time, with valuation and profitability offering the most support. Risk indicators are low, suggesting a relatively contained downside profile.
For informational purposes only. Not financial advice.
Similar stocks to compare
A short list of Drug Manufacturers - Specialty & Generic names that are close enough in size to make side-by-side comparison useful.